Nutriband Inc. (NASDAQ: NTRB), in collaboration with Kindeva, has achieved a milestone in the pharmaceutical industry by scaling up the commercial manufacturing process for Aversa Fentanyl. This product combines Nutriband's AVERSA abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, produced at a U.S.-based facility. The advancement signifies a critical step towards introducing the world's first abuse-deterrent opioid patch to the market, aiming to mitigate the risks of abuse, misuse, and accidental exposure associated with opioids.
The collaboration's next phase involves producing clinical supplies and submitting an Investigational New Drug application to initiate a human abuse liability study. With projections of peak U.S. sales between $80 million and $200 million, Aversa Fentanyl represents not only a potential breakthrough in opioid abuse prevention but also a significant commercial opportunity. Nutriband's extensive international patent portfolio further supports its ambitions for global market penetration.
This development is crucial in the context of the ongoing opioid crisis, offering a promising solution to reduce abuse and misuse of prescription opioids. The successful scale-up of Aversa Fentanyl's manufacturing process underscores the importance of innovation in pharmaceutical technology to address public health challenges, potentially setting a new standard for the development of abuse-deterrent medications.
